These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
697 related articles for article (PubMed ID: 26181259)
1. Association of Somatic Mutations of ADAMTS Genes With Chemotherapy Sensitivity and Survival in High-Grade Serous Ovarian Carcinoma. Liu Y; Yasukawa M; Chen K; Hu L; Broaddus RR; Ding L; Mardis ER; Spellman P; Levine DA; Mills GB; Shmulevich I; Sood AK; Zhang W JAMA Oncol; 2015 Jul; 1(4):486-94. PubMed ID: 26181259 [TBL] [Abstract][Full Text] [Related]
2. Association of BRCA1 and BRCA2 mutations with survival, chemotherapy sensitivity, and gene mutator phenotype in patients with ovarian cancer. Yang D; Khan S; Sun Y; Hess K; Shmulevich I; Sood AK; Zhang W JAMA; 2011 Oct; 306(14):1557-65. PubMed ID: 21990299 [TBL] [Abstract][Full Text] [Related]
4. BRCA testing, treatment patterns and survival in platinum-sensitive recurrent ovarian cancer - an observational cohort study. Unni SK; Schauerhamer MB; Deka R; Tyczynski JE; Fernandes AW; Stevens V; Brixner DI; Stenehjem DD J Ovarian Res; 2016 Mar; 9():18. PubMed ID: 27004793 [TBL] [Abstract][Full Text] [Related]
5. A BRCA1/2 Mutational Signature and Survival in Ovarian High-Grade Serous Carcinoma. Dong F; Davineni PK; Howitt BE; Beck AH Cancer Epidemiol Biomarkers Prev; 2016 Nov; 25(11):1511-1516. PubMed ID: 27496093 [TBL] [Abstract][Full Text] [Related]
6. Gynaecological cancer: ADAMTS mutations predict sensitivity to chemotherapy in ovarian cancer. Errico A Nat Rev Clin Oncol; 2015 Sep; 12(9):504. PubMed ID: 26122182 [No Abstract] [Full Text] [Related]
7. Overall survival in patients with platinum-sensitive recurrent serous ovarian cancer receiving olaparib maintenance monotherapy: an updated analysis from a randomised, placebo-controlled, double-blind, phase 2 trial. Ledermann JA; Harter P; Gourley C; Friedlander M; Vergote I; Rustin G; Scott C; Meier W; Shapira-Frommer R; Safra T; Matei D; Fielding A; Spencer S; Rowe P; Lowe E; Hodgson D; Sovak MA; Matulonis U Lancet Oncol; 2016 Nov; 17(11):1579-1589. PubMed ID: 27617661 [TBL] [Abstract][Full Text] [Related]
8. Tumor mutation burden forecasts outcome in ovarian cancer with BRCA1 or BRCA2 mutations. Birkbak NJ; Kochupurakkal B; Izarzugaza JM; Eklund AC; Li Y; Liu J; Szallasi Z; Matulonis UA; Richardson AL; Iglehart JD; Wang ZC PLoS One; 2013; 8(11):e80023. PubMed ID: 24265793 [TBL] [Abstract][Full Text] [Related]
9. BRCA mutational status, initial disease presentation, and clinical outcome in high-grade serous advanced ovarian cancer: a multicenter study. Petrillo M; Marchetti C; De Leo R; Musella A; Capoluongo E; Paris I; Benedetti Panici P; Scambia G; Fagotti A Am J Obstet Gynecol; 2017 Sep; 217(3):334.e1-334.e9. PubMed ID: 28549976 [TBL] [Abstract][Full Text] [Related]
10. Evidence for a dualistic model of high-grade serous carcinoma: BRCA mutation status, histology, and tubal intraepithelial carcinoma. Howitt BE; Hanamornroongruang S; Lin DI; Conner JE; Schulte S; Horowitz N; Crum CP; Meserve EE Am J Surg Pathol; 2015 Mar; 39(3):287-93. PubMed ID: 25581732 [TBL] [Abstract][Full Text] [Related]
11. The role of tandem duplicator phenotype in tumour evolution in high-grade serous ovarian cancer. Ng CK; Cooke SL; Howe K; Newman S; Xian J; Temple J; Batty EM; Pole JC; Langdon SP; Edwards PA; Brenton JD J Pathol; 2012 Apr; 226(5):703-12. PubMed ID: 22183581 [TBL] [Abstract][Full Text] [Related]
12. Association of somatic mutations in BRCA2 BRC domain with chemotherapy sensitivity and survival in high grade serous ovarian cancer. Zhang G; Zhang J; Zhu Y; Liu H; Shi Y; Mi K; Li M; Zhao Q; Huang Z; Huang J Exp Cell Res; 2021 Sep; 406(1):112742. PubMed ID: 34302857 [TBL] [Abstract][Full Text] [Related]
15. Invasion Patterns of Metastatic Extrauterine High-grade Serous Carcinoma With BRCA Germline Mutation and Correlation With Clinical Outcomes. Hussein YR; Ducie JA; Arnold AG; Kauff ND; Vargas-Alvarez HA; Sala E; Levine DA; Soslow RA Am J Surg Pathol; 2016 Mar; 40(3):404-9. PubMed ID: 26574845 [TBL] [Abstract][Full Text] [Related]
16. Targeting DNA repair: the genome as a potential biomarker. Nesic K; Wakefield M; Kondrashova O; Scott CL; McNeish IA J Pathol; 2018 Apr; 244(5):586-597. PubMed ID: 29282716 [TBL] [Abstract][Full Text] [Related]
17. Landscape of genomic alterations in high-grade serous ovarian cancer from exceptional long- and short-term survivors. Yang SYC; Lheureux S; Karakasis K; Burnier JV; Bruce JP; Clouthier DL; Danesh A; Quevedo R; Dowar M; Hanna Y; Li T; Lu L; Xu W; Clarke BA; Ohashi PS; Shaw PA; Pugh TJ; Oza AM Genome Med; 2018 Oct; 10(1):81. PubMed ID: 30382883 [TBL] [Abstract][Full Text] [Related]
18. Overall survival and updated progression-free survival outcomes in a randomized phase II study of combination cediranib and olaparib versus olaparib in relapsed platinum-sensitive ovarian cancer. Liu JF; Barry WT; Birrer M; Lee JM; Buckanovich RJ; Fleming GF; Rimel BJ; Buss MK; Nattam SR; Hurteau J; Luo W; Curtis J; Whalen C; Kohn EC; Ivy SP; Matulonis UA Ann Oncol; 2019 Apr; 30(4):551-557. PubMed ID: 30753272 [TBL] [Abstract][Full Text] [Related]
19. Distinct homologous recombination gene expression profiles after neoadjuvant chemotherapy associated with clinical outcome in patients with ovarian cancer. Kessous R; Octeau D; Klein K; Tonin PN; Greenwood CMT; Pelmus M; Laskov I; Kogan L; Salvador S; Lau S; Yasmeen A; Gotlieb WH Gynecol Oncol; 2018 Mar; 148(3):553-558. PubMed ID: 29395310 [TBL] [Abstract][Full Text] [Related]
20. Effect of Oophorectomy on Survival After Breast Cancer in BRCA1 and BRCA2 Mutation Carriers. Metcalfe K; Lynch HT; Foulkes WD; Tung N; Kim-Sing C; Olopade OI; Eisen A; Rosen B; Snyder C; Gershman S; Sun P; Narod SA JAMA Oncol; 2015 Jun; 1(3):306-13. PubMed ID: 26181175 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]